We have published early results from our clinical trial of the vaccine ChAdOx1 nCoV-19 (also known as AZD1222), designed by the University of Oxford and developed in partnership with AstraZeneca. The preliminary data shows that it is safe and induced a strong antibody response in all vaccinated volunteers, suggesting that an effective vaccine could be within reach.
Read the full article on The Conversation website, written by Rebecca Ashfield, Jenner Institute.
Oxford is a subscribing member of The Conversation. Find out how you can write for The Conversation.